Three local companies are set to be among the first U.S. biotechs to go public in 2019, hoping to raise $227 million collectively.
Cambridge's TCR2 Therapeutics Inc. and Newton's Stealth BioTherapeutics Corp. are aiming to raise up to $100 million and $86 million, respectively, in IPOs in the new year, according to paperwork filed with the U.S. Securities and Exchange Commission on Friday.
TCR2's filing is especially notable, as the company has yet to launch any clinical trials of its CAR-T cancer…
